Packaging
1.5 mL vial.
Endometritis is a significant reproductive disease in mares, particularly those that are older, barren, or have a history of uterine infections.
Settle® is a mycobacterium cell wall fraction (MCWF) immunostimulant, approved for use in the treatment of equine endometritis caused by Streptococcus zooepidemicus. By activating the immune response within the uterus, Settle® promotes faster uterine clearance, reduces bacterial load, and increases pregnancy success rates in mares with recurrent breeding-related infections.
Why use Settle®:
Offers flexible administration: it can be given intravenously or intrauterine for targeted effect.
Supports uterine recovery post-foaling in mares with poor involution.
Reduces inflammation and promotes optimal reproductive tract health.
Improves conception rates, especially in hard-to-breed mares.
1.5 mL dose per treatment.
Administration routes: Intravenous injection into the jugular vein or intrauterine instillation using a sterile catheter.
Timing: During early estrus (natural or induced); can be repeated at subsequent estrus periods if needed.
Common use cases for Settle® treatment:
At diagnosis of uterine infection while awaiting culture or sensitivity test results.
The day after foaling in mares prone to endometritis or retained placenta.
At first heat post-foaling, to facilitate earlier breeding and increase conception rates.
Before shipping mares for breeding, ensuring optimal reproductive health.
NovaVive Inc. is a Canadian company developing immune-enhancing alternatives to antibiotics using its proprietary MCWF technology—including treatments for equine endometritis and viral respiratory disease. Visit novavive.ca to learn more.
Settle® enhances the innate humoral immune responses by activating macrophages and stimulating the cloning of polymorphonuclear leukocytes (PMN). These activated phagocytic cells stimulate a cytokine cascade that results in the destruction of bacteria, such as Streptococcus zooepidemicus.
Yes, Settle® can be effectively integrated with standard treatment regimens that include antibiotics and uterine lavage. However, it should not be administered concurrently with corticosteroids or adrenocorticotropic hormone (ACTH), as these can reduce the production of IL-1 and diminish the immunostimulant effect.
Store Settle® at 2°–7°C. Do not freeze. Mix thoroughly before injecting. Use the entire contents when first opened.
Yes, do not administer Settle® within 21 days of slaughter.